Overview

Efficacy and Safety of JT001 (VV116) Compared With Favipiravir

Status:
Not yet recruiting
Trial end date:
2022-07-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of JT001 (VV116) for the Treatment of Coronavirus Disease 2019 (COVID-19) in participants with moderate to severe COVID-19.
Phase:
Phase 3
Details
Lead Sponsor:
Shanghai Vinnerna Biosciences Co., Ltd.
Collaborator:
Sponsor GmbH
Treatments:
Favipiravir